Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients
NCT00306553
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
INDUSTRY
Sponsor class
Conditions
Malignant Melanoma
Interventions
BIOLOGICAL:
CYT004-MelQbG10
Sponsor
Cytos Biotechnology AG